bluebird bio, Inc. (NASDAQ:BLUE) had its price objective lifted by equities researchers at Morgan Stanley from $103.00 to $105.00 in a report issued on Monday, Marketbeat.com reports. The firm presently has an “equal weight” rating on the biotechnology company’s stock. Morgan Stanley’s target price would suggest a potential upside of 10.47% from the company’s previous close.

BLUE has been the subject of several other reports. Zacks Investment Research downgraded shares of bluebird bio from a “buy” rating to a “hold” rating in a research note on Tuesday, July 18th. Cantor Fitzgerald set a $37.00 price objective on shares of bluebird bio and gave the company a “sell” rating in a research note on Monday, June 5th. BTIG Research reaffirmed a “buy” rating and set a $112.00 price objective on shares of bluebird bio in a research note on Thursday, June 1st. Wedbush reaffirmed an “outperform” rating on shares of bluebird bio in a research note on Tuesday, June 6th. Finally, Cowen and Company reaffirmed a “buy” rating on shares of bluebird bio in a research note on Friday, June 23rd. Three analysts have rated the stock with a sell rating, six have issued a hold rating and eleven have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $100.66.

bluebird bio (NASDAQ BLUE) traded up 2.52% on Monday, hitting $97.45. The stock had a trading volume of 337,391 shares. The stock’s 50-day moving average is $102.86 and its 200-day moving average is $88.98. bluebird bio has a 52-week low of $37.05 and a 52-week high of $123.75. The company’s market cap is $4.44 billion.

bluebird bio (NASDAQ:BLUE) last issued its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($1.73) EPS for the quarter, missing the consensus estimate of ($1.66) by $0.07. The firm had revenue of $16.70 million for the quarter, compared to the consensus estimate of $6.29 million. bluebird bio had a negative net margin of 1,080.59% and a negative return on equity of 32.19%. The business’s revenue was up 977.4% on a year-over-year basis. During the same period last year, the company posted ($1.59) earnings per share. Analysts expect that bluebird bio will post ($6.69) earnings per share for the current year.

WARNING: “Morgan Stanley Increases bluebird bio, Inc. (BLUE) Price Target to $105.00” was reported by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/08/07/bluebird-bio-inc-nasdaqblue-price-target-raised-to-105-00-at-morgan-stanley.html.

In other bluebird bio news, insider Nick Leschly sold 25,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 27th. The shares were sold at an average price of $108.05, for a total transaction of $2,701,250.00. Following the completion of the transaction, the insider now owns 360,656 shares of the company’s stock, valued at $38,968,880.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Daniel Lynch sold 2,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 25th. The shares were sold at an average price of $80.00, for a total transaction of $160,000.00. Following the transaction, the director now directly owns 3,400 shares of the company’s stock, valued at approximately $272,000. The disclosure for this sale can be found here. Insiders have sold 76,245 shares of company stock valued at $7,938,108 in the last ninety days. Insiders own 3.90% of the company’s stock.

Institutional investors have recently made changes to their positions in the stock. Pictet Asset Management Ltd. increased its position in shares of bluebird bio by 26.2% in the first quarter. Pictet Asset Management Ltd. now owns 182,841 shares of the biotechnology company’s stock worth $16,620,000 after buying an additional 37,925 shares in the last quarter. Bank of New York Mellon Corp increased its position in shares of bluebird bio by 10.7% in the first quarter. Bank of New York Mellon Corp now owns 228,663 shares of the biotechnology company’s stock worth $20,787,000 after buying an additional 22,011 shares in the last quarter. Advisors Asset Management Inc. acquired a new position in shares of bluebird bio during the first quarter worth $858,000. Commerzbank Aktiengesellschaft FI acquired a new position in shares of bluebird bio during the first quarter worth $588,000. Finally, Usca Ria LLC acquired a new position in shares of bluebird bio during the first quarter worth $707,000.

bluebird bio Company Profile

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Analyst Recommendations for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.